Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.08.2019 | Case report

Alectinib

Transformation of lung adenocarcinoma to non-small cell lung cancer following alectinib resistance : case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

A 36-year-old woman developed transformation of lung adenocarcinoma to non-small cell lung cancer following alectinib resistance for anaplastic lymphoma kinase (ALK) rearrangement-positive adenocarcinoma. …
Literatur
Zurück zum Zitat Koyama K, et al. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma. Pathology International 69: 294-299, No. 5, May 2019. Available from: URL: http://doi.org/10.1111/pin.12782 -Japan Koyama K, et al. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma. Pathology International 69: 294-299, No. 5, May 2019. Available from: URL: http://​doi.​org/​10.​1111/​pin.​12782 -Japan
Metadaten
Titel
Alectinib
Transformation of lung adenocarcinoma to non-small cell lung cancer following alectinib resistance : case report
Publikationsdatum
01.08.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-65776-6

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Clozapine

Case report

Chlorphenamine

Case report

Bevacizumab